CommercialCoverageMedium impact
08.00.34w, Intravenous Infliximab and Related Biosimilars
Independence Blue Cross·Rheumatology, Gastroenterology, Dermatology +1 more·Pharmacy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
Policy 08.00.34w regarding Intravenous Infliximab and Related Biosimilars has been updated for commercial plans. The policy was effective October 1, 2025 but was posted and removed on the same day (November 17, 2025), suggesting this may be a temporary update or correction to the original policy.
Action Required
By December 15, 2025: Billing team must review the updated Intravenous Infliximab and Related Biosimilars policy at the source URL to understand specific changes to coverage, prior authorization, or billing requirements. Contact IBX directly if policy details are needed since the policy was removed the same day it was posted. Update billing protocols accordingly for any infliximab-related treatments.